PhaseBio Pharmaceuticals IPO Research Information

PhaseBio Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on PhaseBio Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
PhaseBio Pharmaceuticals	PHAS - NASDAQ	$12.00-$14.00	$5.00	$5.00	9.2 million	10/18/2018
Underwriter(s): Citigroup, Cowen, Stifel
Co-Manager(s): Needham & Company
Industry: Health Care
Filing(s): Filed 2018-09-21 Terms Added 2018-10-05

PhaseBio Pharmaceuticals Quote & Chart - Click for current quote - PHAS

About PhaseBio Pharmaceuticals (adapted from PhaseBio Pharmaceuticals prospectus):
They are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "PHAS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.